June 02, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →The DEA placed 3-Methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, impacting clinicians encountering similar dissociative substances.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, classifying it as having a high potential for abuse and no accepted medical use.
Read more →The DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances concurrently with cannabis.
Read more →Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA temporarily placed 2-Fluorodeschloroketamine in Schedule I, potentially impacting research and clinical use should this substance be considered alongside or as an alternative to cannabis-based treatments.
Read more →Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
This action places 4-fluoroamphetamine in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, which may impact research involving similar chemical structures to cannabis compounds.
Read more →The DEA placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, meaning these synthetic opioids have no accepted medical use and high abuse potential, potentially impacting differential diagnoses for clinicians.
Read more →The DEA placed N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, impacting clinicians by restricting their use and potentially affecting patient access due to federal control.
Read more →The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinicians and patients encountering these substances.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the US.
Read more →Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.
Read more →Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I
The DEA placed 4-Chloromethcathinone in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, impacting clinicians assessing patient substance use.
Read more →The DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians and patients through potential cross-contamination of unregulated products or misidentification as cannabis.
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.
Read more →This DEA rule places seven fentanyl-related substances into Schedule I, potentially impacting clinicians evaluating patients with pain who may be considering or currently using these opioids alongside cannabis.
Read more →The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians and patients due to potential misidentification or adulteration of products.
Read more →The DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances alongside cannabis.
Read more →Exempt Chemical Preparations Under the Controlled Substances Act
The FDA clarified that certain hemp-derived cannabinoid products meeting specific criteria are exempt from the Controlled Substances Act, potentially impacting legal access for clinicians and patients.
Read more →Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I
The DEA temporarily placed seven synthetic opioids in Schedule I, potentially impacting research and access, though this action does not directly affect cannabis or its clinical use.
Read more →The DEA placed 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, classifying it as having a high potential for abuse and no currently accepted medical use, which may impact research or clinical considerations involving similar substances.
Read more →Digest-Level Clinical Commentary
Clinical Reflection As a cannabis medicine practitioner, I observe that this digest consists almost entirely of synthetic drug scheduling actions involving opioids, benzodiazepines, cathinones, and novel psychoactive substances, with no cannabis-specific scheduling changes among the 20 items listed. This pattern suggests that regulatory attention remains concentrated on addressing the emergence of illicit synthetic compounds and analogs rather than on cannabis plant material or its primary cannabinoids, which reflects the current regulatory landscape where cannabis scheduling differs fundamentally from these synthetic drugs despite ongoing federal classification. For my clinical practice, this underscores that cannabis medicine operates within a distinct regulatory framework shaped more by state-level legalization movements than by federal drug scheduling actions, meaning my evidence-based prescribing decisions continue to depend primarily on state medical board guidance and evolving clinical literature rather than on federal scheduling changes
These scheduling actions reflect the ongoing regulatory response to the proliferation of novel synthetic drugs designed to evade existing drug laws through minor chemical modifications. The majority of these substances are synthetic cannabinoids and novel opioids that have appeared in illicit drug supplies with increasing frequency, often associated with serious adverse effects and overdose deaths. The repeated scheduling of structurally similar compounds and the use of temporary scheduling authority suggest that clandestine manufacturers continue to outpace regulatory processes, necessitating rapid government response to emerging threats.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
